Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

January 31, 2012

Conditions

Growth Hormone Deficiency

Interventions

DRUG

Somatropin

A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin

DRUG

Placebo

Tablets, oral administrations

Trial Locations (1)

Seoul National University Hospital,Clinical Trial Center/ Clinical Research Institute, Seoul